 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||
4 October 2005 | Volume 143 Issue 7 | Pages 522-536
Background: Therapeutic phlebotomy for hereditary hemochromatosis is relatively safe and presumably efficacious when offered before cirrhosis develops, so screening primary care patients is of substantial interest.
Purpose: To conduct a systematic review of the evidence on 1) the prevalence of the disease in primary care, 2) the risk for morbid or fatal complications for untreated patients, 3) the diagnostic usefulness of transferrin saturation and serum ferritin level in identifying early disease, 4) the efficacy of early treatment, and 5) whether the benefits of screening outweigh the risks.
Data Sources: MEDLINE search from 1966 through April 2004, complemented by reference review of identified original studies and review articles published in English.
Study Selection: PubMed Clinical Queries filters search of prognosis, diagnosis, etiology, or treatment were used depending on the question. Two authors reviewed all titles and abstracts.
Data Extraction: Two investigators independently reviewed extracted data.
Data Synthesis: The prevalence of hereditary hemochromatosis was 1 in 169 patients to 1 in 556 patients (n = 3 studies). Uncontrolled, prospective studies of genetic homozygous patients did not consistently identify a link to overt hereditary hemochromatosis. A serum ferritin level less than 1000 µg/L was predictive of absence of cirrhosis. Six studies demonstrated reduced survival in patients with cirrhosis. Diagnostic studies varied with respect to case definition. No blinded, independent comparisons of screening tests with the gold standard (biopsy or results of quantitative phlebotomy) or randomized, controlled trials of phlebotomy were identified. Cost-effectiveness analysis was limited by lack of prospective data on the natural history of the disease.
Limitations: Varied case definition and lack of prospective cohort studies or randomized trials.
Conclusions: The available evidence does not demonstrate that benefits outweigh the risks and costs of screening for hemochromatosis.
Author and Article Information
From Loyola University Medical Center, Maywood, Illinois; Hines Veterans Affairs Medical Center, Hines, Illinois; and Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Grant Support: The paper was written under contract with the American College of Physicians.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Brian Schmitt, MD, MPH, Medicine and Neurology Service Line (111), Hines Veterans Affairs Hospital, Hines, IL 60141; e-mail, brian.schmitt2{at}med.va.gov.
Current Author Addresses: Dr. Schmitt: Medicine and Neurology Service Line (111), Hines Veterans Affairs Hospital, 5th Avenue and Roosevelt, Hines, IL 60141.
Dr. Golub: Northwestern University, 676 North St. Clair, Suite 200, Chicago, IL 60611.
Dr. Green: Northwestern University, 303 East Chicago Avenue, Chicago, IL 60611. CLINICAL GUIDELINES
Screening Primary Care Patients for Hereditary Hemochromatosis with Transferrin Saturation and Serum Ferritin Level: Systematic Review for the American College of Physicians
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  C. M. Francucci, C. Gatti, A. Camilletti, P. Fiscaletti, R. Caudarella, and M. Boscaro Hypogonadism and Reduced Bone Mineral Density in Heterozygous H63D Mutation in the HFE Gene: An Unusual Presentation of Hereditary Hemochromatosis J Androl, January 1, 2007; 28(1): 21 - 26. [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Whitlock, B. A. Garlitz, E. L. Harris, T. L. Beil, and P. R. Smith Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med, August 1, 2006; 145(3): 209 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Swinkels, M. C.H. Janssen, J. Bergmans, and J. J.M. Marx Hereditary Hemochromatosis: Genetic Complexity and New Diagnostic Approaches Clin. Chem., June 1, 2006; 52(6): 950 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Should Routine Screening for Hereditary Hemochromatosis Be Provided in Primary Care Practices? Journal Watch Gastroenterology, January 3, 2006; 2006(103): 2 - 2. [Full Text]
|
|
|
|
 |
|
 Screening for Hemochromatosis: ACP Practice Guideline Journal Watch (General), October 18, 2005; 2005(1018): 1 - 1. [Full Text]
|
|
|
|
|
|
A. Qaseem, M. Aronson, N. Fitterman, V. Snow, K. B. Weiss, D. K. Owens, and for the Clinical Efficacy Assessment Subcommittee Screening for Hereditary Hemochromatosis: A Clinical Practice Guideline from the American College of Physicians Ann Intern Med, October 4, 2005; 143(7): 517 - 521. [Abstract] [Full Text] [PDF]
|
|
Read all Rapid Responses
Article
